Investigational drug · Phase 3
aglatimagene besadenovec
Also called: CAN-2409, AdV-tk
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
17
Any phase or sponsor naming "aglatimagene besadenovec"
First trial start
2011
Sep 2011
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "aglatimagene besadenovec", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
- Prostate Cancer Patients Treated by Radiotherapy
- Prostate Cancer (Adenocarcinoma)
- Non Small Cell Lung Cancer
- Non-squamous, Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "aglatimagene besadenovec" as an intervention, largest first.
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerPivotal-lookingActive, not recruiting
Candel Therapeutics, Inc.Industry
NCT01436968 · 711 participants (planned) · Start Sep 2011 · Primary completion Aug 2024
Drug: Aglatimagene besadenovec + valacyclovir; Placebo + valacyclovir · For: Prostate Cancer
Sites: Gilbert, Arizona; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)Pivotal-lookingRecruiting
Candel Therapeutics, Inc.Industry
NCT07660094 · 500 participants (planned) · Start Jun 15, 2026 · Primary completion Oct 22, 2031
Drug: Aglatimagene Besadenovec; Valacyclovir and 2 more · For: Non-squamous, Non-Small Cell Lung Cancer
Sites: New York, New York
- Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Pivotal-lookingActive, not recruiting
Candel Therapeutics, Inc.Industry
NCT02768363 · 187 participants · Start May 2016 · Primary completion Nov 2024
Drug: aglatimagene besadenovec; placebo and 1 more · For: Prostate Cancer
Sites: Golden, Colorado; Chicago, Illinois; New Orleans, Louisiana · 23 sites in all
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCPivotal-lookingStatus unknown
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT03313596 · 180 participants (planned) · Start Mar 2013 · Primary completion Dec 2019
Drug: ADV-Tk · For: Hepatocellular Carcinoma
Sites: Beijing, China; Changsha, China; Chengdu, China · 11 sites in all
- CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruiting
Candel Therapeutics, Inc.Industry
NCT04495153 · 90 participants · Start Oct 13, 2020 · Primary completion Dec 31, 2024
Drug: Aglatimagene besadenovec; Valacyclovir and 2 more · For: Non Small Cell Lung Cancer
Sites: Phoenix, Arizona; Farmington, Connecticut; New Haven, Connecticut · 14 sites in all
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT02202564 · 81 participants · Start Oct 2006 · Primary completion Oct 2011
Drug: ADV-TK; ganciclovir · For: Liver Cancer; Hepatocellular Carcinoma
The Methodist Hospital Research InstituteAcademic, hospital or other
NCT03541928 · 60 participants (planned) · Start Aug 2, 2018 · Primary completion Jul 2023
Drug: HSV-Tk; Valacyclovir and 2 more · For: High-risk Prostate Cancer; Prostate Cancer
Sites: Houston, Texas
- Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaStatus unknown
Candel Therapeutics, Inc.Industry
NCT02446093 · 54 participants (planned) · Start Oct 2015 · Primary completion Dec 2025
Drug: Aglatimagene besadenovec · For: Borderline Resectable Pancreatic Adenocarcinoma
Sites: Fort Myers, Florida; Columbus, Ohio; Mexico City, Mexico
Candel Therapeutics, Inc.Industry
NCT00589875 · 52 participants · Start Mar 2007 · Primary completion Dec 2015
Drug: CAN-2409; Valacyclovir and 1 more · For: Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma and 1 more
Sites: Duarte, California; Chicago, Illinois; Columbus, Ohio · 4 sites in all
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT00870181 · 47 participants · Start Jan 2008 · Primary completion Dec 2011
Drug: ADV-TK/GCV; systemic chemotherapy · For: Malignant Glioma of Brain; Glioblastoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.
Aggarwal C, Sterman D, Dwyer J, et al. · J Immunother Cancer 2026
- Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
DeWeese TL, Manzanera A, Sylvester J, et al. · Lancet Oncol 2026
- The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.
Velammal PNKP, Dhasakeerthi T, Varghese JR, et al. · Childs Nerv Syst 2025
- A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.
Wen PY, Manzanera A, Duault C, et al. · Neuro Oncol 2025
- Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy.
Diers AR, Guo Q, Li Z, et al. · Cancer Res Commun 2025
- Gene therapy for people with hepatocellular carcinoma.
Naing C, Ni H, Aung HH, et al. · Cochrane Database Syst Rev 2024
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.